Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Recent longitudinal studies of glioblastoma (GBM) have demonstrated a lack of apparent
selection pressure for specific DNA mutations in recurrent disease. Single-cell lineage …

Glioblastoma multiforme (GBM) is acknowledged as the most aggressive primary brain
tumor in adults. It is typically characterized by the high heterogeneity which corresponds to …

Glioblastoma (GBM) is the most common and aggressive malignancy involving human
brain, with a poor prognosis. Although various advanced treatment strategies have been …

Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in
adults. As supplements to standard of care (SOC), various immunotherapies improve the …

Among the diverse sources of neoantigens (ie single-nucleotide variants (SNVs), insertions
or deletions (Indels) and fusion genes), fusion gene-derived neoantigens are generally …

Background Glioblastoma is one of the most devastating cancer worldwide based on its
locally aggressive behavior and because it cannot be cured by current therapies. Defects in …

Despite advancements in cancer immunotherapy, solid tumors remain formidable
challenges. In glioma, profound inter-and intra-tumoral heterogeneity of antigen landscape …

Immunity is governed by fundamental genetic processes. These processes shape the nature
of immune cells and set the rules that dictate the myriad complex cellular interactions that …